Kuvan

Sapropterin dihydrochloride, the active ingredient in Kuvan, is a synthetic tetrahydrobiopterin (BH4) analog presented as an oral tablet for systemic use. It is indicated for patients with phenylketonuria who respond to BH4 therapy and for the management of hyperphenylalaninemia, helping to lower elevated blood phenylalanine levels through enhanced enzymatic conversion of phenylalanine to tyrosine. GNH USA supplies Kuvan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

Kuvan is employed in the management of disorders of phenylalanine metabolism, primarily phenylketonuria and related conditions. Phenylketonuria (BH4‑responsive): lowers blood phenylalanine concentrations, enabling a less restrictive diet and improved metabolic control. Hyperphenylalaninemia: reduces elevated phenylalanine levels in patients with this metabolic imbalance. Phenylalanine hydroxylase deficiency: provides cofactor support to enhance residual enzyme activity, aiding in phenylalanine clearance.

Adverse reactions reported with Kuvan are generally mild, but serious events can occur and require medical attention. Common Side Effects: - Headache - Nausea - Vomiting - Abdominal pain - Fatigue - Rash Serious or Rare Side Effects: - Anaphylactic reaction - Severe allergic dermatitis - Eosinophilia - Elevated liver enzymes - Seizures (rare)

Kuvan should be used with attention to specific safety considerations to minimise risk. Pregnancy: Category B; use only when potential benefit justifies the potential risk to the fetus. Breastfeeding: Caution advised; monitor infant for possible adverse effects. Renal impairment: Adjust monitoring; use with care in patients with reduced kidney function. Pediatric use: Safety and efficacy established in children with BH4‑responsive PKU; dosing individualized. Concomitant diet: Maintain phenylalanine‑restricted diet as prescribed; drug does not replace dietary management. Store at room temperature: Keep tablets in original packaging, protect from moisture and excessive heat.

Kuvan may interact with other substances that affect phenylalanine metabolism or drug absorption. Major Interactions (Avoid): - Phenylalanine supplements: can negate the drug’s effect by increasing phenylalanine load. - Concurrent use of other BH4 analogues: may lead to excessive cofactor levels and unpredictable metabolic response. Moderate Interactions (Monitor Closely): - Antihistamines: may increase risk of rash when combined with Kuvan. - Oral contraceptives: may alter phenylalanine metabolism; monitor phenylalanine levels. - Thyroid hormone replacement therapy: potential interaction affecting metabolic rate; observe thyroid function tests.